Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ligand Pharmaceuticals Inc

NASDAQ: LGND · Life Sciences · 11 alerts · CIK 886163

Share price
$301.71Close, Nov 16
Market cap
$6.04B
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ligand Pharmaceuticals Inc filings on SEC EDGAR ↗

4:32 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider John W. Kozarich Sells $162K of Stock

John W. Kozarich sold 500 shares of Ligand Pharmaceuticals Inc at $325.00 a share, worth $162K in total on Nov 12, 2026. Shares held after the trade: 42,122 (-1.2%).

Value
$162K
Shares
500
Price
$325.00
Holding change
-1.2%
Trade date
Nov 12, 2026
4:26 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Martine Zimmermann Sells $636K of Stock

Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals Inc at $318.17 a share, worth $636K in total on Nov 12, 2026. Shares held after the trade: 1,782 (-52.9%).

Value
$636K
Shares
2,000
Price
$318.17
Holding change
-52.9%
Trade date
Nov 12, 2026
4:49 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $957K of Stock

Jason Aryeh sold 2,990 shares of Ligand Pharmaceuticals Inc at $319.99 to $320.20 a share (average $320.05) in 5 transactions, worth $957K in total on Nov 10, 2026. Shares held after the trade: 105,476 (-0.5%).

Value
$957K
Shares
2,990
Average price
$320.05
Holding change
-0.5%
Trade date
Nov 10, 2026
5:42 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $90.2K of Stock

Jason Aryeh sold 282 shares of Ligand Pharmaceuticals Inc at $319.99 a share, worth $90.2K in total on Nov 4, 2026. Shares held after the trade: 108,476 (-0.3%).

Value
$90.2K
Shares
282
Price
$319.99
Holding change
-0.3%
Trade date
Nov 4, 2026
4:23 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals CLO & Secretary Andrew Reardon Sells $1.57M of Stock

Andrew Reardon, CLO & Secretary, sold 5,000 shares of Ligand Pharmaceuticals Inc at $307.39 to $323.14 a share (average $313.22) in 13 transactions, worth $1.57M in total on Nov 2, 2026. Shares held after the trade: 31,854 (-0.4%).

Value
$1.57M
Shares
5,000
Average price
$313.22
Role
CLO & Secretary
Holding change
-0.4%
Trade date
Nov 2, 2026
7:39 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $676K of Stock

Jason Aryeh sold 2,111 shares of Ligand Pharmaceuticals Inc at $317.74 to $320.49 a share (average $320.30) in 6 transactions, worth $676K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 108,758 (-0.6%).

Value
$676K
Shares
2,111
Average price
$320.30
Holding change
-0.6%
Trade date
Oct 30, 2026 to Nov 2, 2026
4:47 PM ET 10-Q
Financial Results

Ligand Pharmaceuticals Q3 2026 Results: Net Loss of $28.5M

For the nine months ended September 30, 2026, Ligand Pharmaceuticals reported total revenues and income of $194.2 million and net income of $6.7 million, a decrease from $79.7 million in the prior year period. The company significantly expanded its balance sheet through the acquisition of XOMA, resulting in total assets increasing to $2.24 billion compared to $1.56 billion at year-end 2025.

Key figure
Net loss $28.5M
7:15 AM ET 8-K
Financial Results

Ligand Pharmaceuticals Financial Results

Ligand Pharmaceuticals reported Q3 2026 financial results, highlighted by a 51% year-over-year increase in royalty revenue to $70.3 million, driven by the XOMA portfolio and commercial momentum of Filspari. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75 while reaffirming its total revenue guidance.

Term
Q3 2026

“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”

Todd Davis, CEO of Ligand
4:36 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals CLO & Secretary Andrew Reardon Sells $1.52M of Stock

Andrew Reardon, CLO & Secretary, sold 4,983 shares of Ligand Pharmaceuticals Inc at $302.51 to $307.19 a share (average $304.06) in 5 transactions, worth $1.52M in total on Oct 2, 2026. Shares held after the trade: 31,871 (-0.7%).

Value
$1.52M
Shares
4,983
Average price
$304.06
Role
CLO & Secretary
Holding change
-0.7%
Trade date
Oct 2, 2026
7:09 AM ET 8-K
M&A Deal

Ligand Pharmaceuticals Signs $23M M&A Deal with Sydnexis, Inc.

Ligand Pharmaceuticals acquired royalty and milestone payment rights for Ryjunea from Sydnexis for $23 million upfront. Ryjunea is a treatment for pediatric myopia licensed to Santen Pharmaceutical in the EMEA region, where it is already approved. Ligand will receive tiered royalties ranging from low-double-digits to high-teens on net sales in those territories.

Value
$23M
Counterparty
Sydnexis, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.